Moe R E, Moe K S, Porter P, Gown A M, Ellis G, Tapper D
Department of Surgery, University of Washington School of Medicine, Seattle.
Am J Surg. 1991 May;161(5):580-3. doi: 10.1016/0002-9610(91)90904-r.
Her-2/neu protein product was immunocytochemically analyzed in 139 breast cancers. Epidermal growth factor receptors were similarly analyzed in 74 breast cancers from the same patient pool. These results were also separated on the basis of estrogen receptor proteins and of combined aneuploidy with elevated S-phase from flow cytometry. Invasive breast cancer yielded a positive label for Her-2/neu protein (26%) and for epidermal growth factor receptor (25%), with no significant difference. Correlations with estrogen receptor labeling yielded differences significant inversely for both Her-2/neu protein (p less than 0.02) and epidermal growth factor receptor (p less than 0.01). Positive Her-2/neu protein labels correlated with a positive combination of aneuploidy and elevated S-phase (37%) and a negative combination of aneuploidy and elevated S-phase (21%), with a statistically nonsignificant difference. Positive epidermal growth factor receptor cases with aneuploidy and an elevated S-phase (75%) and without aneuploidy and elevated S-phase (42%) did differ with significance at p less than 0.05. There were eight cases positive for both Her-2/neu protein and epidermal growth factor receptor, four of six cases with negative estrogen receptor, four of six cases with negative estrogen receptor, six of six cases aneuploid, and five of six cases with an elevated S-phase. All eight cases had threatening disease--either stage III or stage IV, with one case of extensive ductal carcinoma in situ (comedo). Correlation of negative Her-2/neu protein with negative epidermal growth factor receptor was significant (p less than 0.05) in 74 cases. However, positive Her-2/neu protein did not correlate with positive epidermal growth factor receptor; there was a trend toward inverse correlation. We conclude that epidermal growth factor receptor labeling results show similarities to Her-2/neu protein results, but epidermal growth factor receptor tended to correlate with unfavorable ploidy and S-phase. Epidermal growth factor receptor labeling might be useful in breast cancers with macrocysts reported to show high epidermal growth factor activity.
对139例乳腺癌进行了Her-2/neu蛋白产物的免疫细胞化学分析。对来自同一患者群体的74例乳腺癌同样进行了表皮生长因子受体分析。这些结果还根据雌激素受体蛋白以及流式细胞术中非整倍体与S期升高的组合进行了分类。浸润性乳腺癌中Her-2/neu蛋白（26%）和表皮生长因子受体（25%）呈阳性标记，无显著差异。与雌激素受体标记的相关性显示，Her-2/neu蛋白（p<0.02）和表皮生长因子受体（p<0.01）均呈显著负相关。Her-2/neu蛋白阳性标记与非整倍体和S期升高的阳性组合（37%）以及非整倍体和S期升高的阴性组合（21%）相关，差异无统计学意义。表皮生长因子受体阳性病例中，有非整倍体和S期升高的情况（75%）以及无非整倍体和S期升高的情况（42%），差异有统计学意义（p<0.05）。有8例Her-2/neu蛋白和表皮生长因子受体均呈阳性，其中6例中有4例雌激素受体阴性，6例中有4例雌激素受体阴性，6例中有六例非整倍体，6例中有5例S期升高。所有8例均患有威胁性疾病——III期或IV期，其中1例为广泛导管原位癌（粉刺型）。在74例病例中，Her-2/neu蛋白阴性与表皮生长因子受体阴性的相关性显著（p<0.05）。然而，Her-2/neu蛋白阳性与表皮生长因子受体阳性不相关；存在负相关趋势。我们得出结论，表皮生长因子受体标记结果与Her-2/neu蛋白结果相似，但表皮生长因子受体往往与不良的倍性和S期相关。表皮生长因子受体标记可能对据报道显示高表皮生长因子活性的大囊肿性乳腺癌有用。
